(1) The labeling would definitely help prevent serious adverse events;
(2) Few patients would be willing to take the drug and risk developing diabetes given that numerous studies have shown Zyprexa to be no more effective than the older class of antipsychotics that do not cause diabetes; and
(3) Most patients on Zyprexa would learn that the drug is not FDA approved to treat the condition they have.
---


